Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound   Target Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound

---

Query: EC:2.7.1.1 (hexokinase)
5,274 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The truncated gene of hexokinase, mini-hexokinase, starting with methionine 455 and ending at the C terminus was expressed in Escherichia coli. Mini-hexokinase lost its ability to ameliorate inhibition of glucose-6-P-inhibited mini-hexokinase in the presence of phosphate (P(i)). We suggest that the P(i) site either resides in the N-terminal half of hexokinase I or requires the N-terminal portion of the enzyme. Site-directed mutagenesis was performed to obtain two mutants of mini-hexokinase: C606S and C628S. Both are thought to be associated with the active site of hexokinase I. These mutants exhibited a 3-fold increase in Km for glucose but no change in either the Km for ATP or the kcat. The circular dichroism (CD) spectra showed no differences among the wild-type or mutant enzymes. These results suggest that Cys606 and Cys628 are not involved in glucose binding directly. The putative ATP-binding site of full-length human brain hexokinase may involve Arg539 and Gly679, and these residues were mutated to Ile. For the mutant R539I, the kcat value decreased 114-fold relative to wild-type hexokinase, whereas the Km values for ATP and glucose changed only slightly. No change was observed in the Ki value for 1,5-anhydroglucitol 6-phosphate. CD spectra showed only a slight change in secondary structure. For the mutant G679I, overexpressed hexokinase is insoluble. We suggest that Arg539 is important for catalysis because it stabilizes the transition state product ADP-hexokinase. Gly679 is probably important for proper folding of the protein.
...
PMID:Active site residues of human brain hexokinase as studied by site-specific mutagenesis. 773 85

A variety of stressful conditions, such as heat shock, ethanol, osmotic shock, glucose deprivation, and oxidative stress, are known to induce the synthesis of specific proteins. Here, we report the induction in Escherichia coli of a protein elicited in response to a hitherto unidentified stress condition, i.e., the overexpression of foreign proteins. The induced protein identified as glucokinase (EC 2.7.1.2) is produced at a level > or = 20-fold higher than the level in wild-type E. coli when foreign proteins are expressed under the control of the alkaline phosphatase (phoA) promoter. The bacterial glucokinase is shown to have a mass of approximately 47 kDa determined by a "renaturation activity stain assay" in situ following sodium dodecyl sulfate-poly-acrylamide gel electrophoresis and exhibits a high specificity for the phosphorylation of glucose. The apparent Km values for glucose and ATP for the enzyme are 0.15 and 0.50 mM, respectively, indicating that the E. coli enzyme is a low Km glucose hexokinase. The enzyme cross-reacts with rabbit antisera raised against hexokinase from higher eukaryotes, implicating some sequence similarity with mammalian hexokinases. Under normal conditions, E. coli glucokinase plays a minor role in glucose metabolism. However, under anabolic stress conditions, this glycolytic enzyme may be required to supplement levels of glucose 6-phosphate. Alternatively, glucokinase, which is predicted in analogy to other hexose-utilizing kinases to have structural folds characteristic of hsp 70, may itself, or in combination with other E. coli proteins, function in the stabilization of newly synthesized proteins.
...
PMID:Glucokinase of Escherichia coli: induction in response to the stress of overexpressing foreign proteins. 778 44

Renal oncocytomas, which have previously been shown to originate from the collecting duct system, were induced in male Sprague-Dawley rats by oral administration of N-nitrosomorpholine (NNM) for 7 weeks. The expression of glucose transporter isoforms GLUT1 and GLUT2, and of several enzymes involved in glucose metabolism [hexokinase (HK), pyruvate kinase (PK), lactate dehydrogenase (LDH), malate dehydrogenase (MDH)] were studied by cytochemical approaches in serial cryostat sections of the kidney 12, 23 and 34 weeks after withdrawal of NNM. Oncocytic tubules connected with collecting ducts were first observed 23 weeks, and oncocytomas 34 weeks after withdrawal. The cytochemical pattern of oncocytic tubules and oncocytomas was similar, but differed markedly from that of normal collecting ducts in nearly all variables studied; expression of GLUT1 and hexokinase I proteins were strongly increased; activities of HK, PK and MDH were elevated, while LDH activity was reduced. These results suggest that oncocytic transformation is associated with fundamental changes in energy metabolism which differ from those in cell lineages leading to other types of renal cell tumours, such as clear/acidophilic and basophilic cell tumours. The characteristic over-expression of GLUT1 may be used as a diagnostic criterion for the discrimination between oncocytes and acidophilic (granular) cells in clear/acidophilic renal cell tumours which show a reduced expression of this glucose transporter protein.
...
PMID:Over-expression of glucose transporter isoform GLUT1 and hexokinase I in rat renal oncocytic tubules and oncocytomas. 792 15

Phosphorylation of glucose by hexokinase is the key step in glucose and energy metabolism of the cell. In the Morris hepatoma 3924A, hexokinase II is the predominant hexokinase isoenzyme and occurs in the cytosol as well as bound to membranes. Hexokinase II was isolated by DEAE-cellulose chromatography from both the cytosolic and the mitochondria-enriched fractions and further resolved by hydrophobic-interaction chromatography on phenyl-Sepharose into two components designated hexokinase IIa and IIb. In both the soluble and the mitochondria-enriched fractions, type IIb was the predominant form, but the IIb/IIa ratio was higher in the particulate (6-8) as compared with the cytosolic fraction (1.5-2.0). Binding of the isolated forms of the enzyme to rat liver mitochondria resulted in a 2-10-fold activation of both subtypes. Biochemical characterization showed that both subtypes are closely related to the isoenzyme commonly referred to as hexokinase II, and that the microheterogeneity was not a consequence of contamination with hexokinase I or III. Both subtypes had a molecular mass of 110 kDa, they were inhibited by Pi at concentrations higher than 5 mM, and activated by the detergent CHAPS. The two subtypes differed in electrophoretic mobility (IIa > IIb), in Km values for glucose (IIa, 0.109 mM; IIb, 0.216 mM), in Ki values for glucose 6-phosphate (IIa, 25 microM; IIb, 0.106 mM), and in Ki values for glucose 1,6-biphosphate (IIa, 12.2 microM; IIb, 5.5 microM). An artificial proteolytic cleavage as cause of the hexokinase II microheterogeneity can be excluded, since both subtypes show the same molecular mass and the ability to bind to mitochondria and phenyl-Sepharose. In addition, the relative proportions of the two subtypes did not vary markedly between several enzyme preparations. Northern-blot analysis with a hexokinase II-specific cDNA probe revealed two distinct mRNA transcripts of 5.2 and 6.3 kb in length, which offers the possibility that hexokinase II microheterogeneity is due to differential RNA transcription and/or processing.
...
PMID:Microheterogeneity of cytosolic and membrane-bound hexokinase II in Morris hepatoma 3924A. 794 51

The activity, intracellular distribution and mRNA expression of hexokinase isoenzymes were studied in normal rat liver, and in epithelial liver cells at different stages of neoplastic transformation, including non-tumorigenic and tumorigenic cell lines. In contrast to liver, all transformed cells exhibited only hexokinase I and II, which both showed significantly increased activity, hexokinase II being the more abundant form. In parallel, the mRNA expression of the two isoenzymes was elevated, indicating transcriptional control of gene expression. Hexokinase I and II were found in the cytosol and bound to mitochondrial membranes; the percentage of membrane-bound enzyme activity increased with the grade of transformation from 32% of total activity in normal liver up to 69% in dedifferentiated tumor cells. The ratio of hexokinase I/II was higher in the membrane fraction than in the cytosol. In all tissues studied hexokinase II could be resolved in two subtypes IIa and IIb by hydrophobic interaction chromatography. The relative proportion of cytosolic IIa and IIb varied significantly between normal liver (1:1) and transformed cells, and among cells of different transformation stages (4:1 to 1:10). IIa demonstrated the main activity in the more differentiated, IIb in the less differentiated cell lines. IIa-activity showed a good correlation with the intracellular glucose 6-phosphate concentration of the cells. The data indicate that neoplastic cell transformation is accompanied by progressive alterations in the proportion and subcellular distribution of hexokinase isoenzymes I and II.
...
PMID:Differences in expression and intracellular distribution of hexokinase isoenzymes in rat liver cells of different transformation stages. 794 23

Glucose metabolism and glucose-stimulated insulin secretion are thought to be controlled at the level of glucose phosphorylation in pancreatic islet beta-cells. In the current study we have investigated the importance of glucose phosphorylation by using recombinant adenovirus as a gene delivery system for isolated rat islets. Treatment of islets with a virus containing the cDNA encoding the Escherichia coli beta-galactosidase gene (AdCMV-beta GAL) resulted in efficiencies of gene transfer of 70.3 +/- 2.5 and 61.2 +/- 2.2% in two independent experiments. Treatment of islets with a virus containing the cDNA encoding rat hexokinase I (AdCMV-HKI) resulted in a 10.7-fold increase in immunodetectable hexokinase protein and a similar increase in enzyme activity. A large percentage of the overexpressed hexokinase activity was associated with a cell fraction enriched in mitochondria. These changes in enzyme level were accompanied by a 2-fold increase in insulin release and [5-3H]glucose usage at basal glucose concentrations (3 mM). The rate of glucose usage at 20 mM glucose and the magnitude of the insulin secretory response to this stimulatory level of the sugar were unchanged relative to control islets. Overexpression of hexokinase I in isolated islets therefore creates a phenotype of elevated basal insulin release similar to that seen in islets from obese and insulin-resistant mammals. The discrepancy between the large increase in hexokinase activity and the small increase in glucose usage and insulin release may indicate, however, that other steps in glucose metabolism become rate-limiting after only modest increases in glucose-phosphorylating activity.
...
PMID:Overexpression of hexokinase I in isolated islets of Langerhans via recombinant adenovirus. Enhancement of glucose metabolism and insulin secretion at basal but not stimulatory glucose levels. 806 45

Glycolytic oscillations can be induced by adding glucose to starved Saccharomyces cerevisiae cells and, after a steady state has been established, cyanide. Transient oscillations or limit-cycle oscillations can be induced depending on the growth phase in which the cells are harvested. To find what causes these differences in the dynamic behaviour, we analyzed glycolytic enzyme activities at different growth phases. The hexokinase activity increased by a factor of three after growth substrate transition from glucose to ethanol; the other measured activities remained constant. Cyanide was found not only to block respiration, but also to trap acetaldehyde. Both cyanide actions appear necessary for the occurrence of sustained glycolytic oscillations.
...
PMID:Yeast cells with a specific cellular make-up and an environment that removes acetaldehyde are prone to sustained glycolytic oscillations. 813 43

In sporadic Alzheimer's disease (AD), a number of metabolic alterations to the brain have been observed soon after the onset of the initial clinical symptoms. In particular, impairments of glucose utilization and related metabolic pathways are prominent and well-established findings in incipient AD, resembling metabolic abnormalities such as have been found in noninsulin-dependent diabetes mellitus. To mimic these abnormalities, we administered an intracerebroventricular (icv) injection of streptozotocin (STZ) to rats and studied the effects of glucose and glycogen metabolism in the cerebral cortex and hippocampus compared with controls. The enzymatic activities studied dropped significantly by 10-30% in brain cortex (cort.) and hippocampus (hc) 3 and 6 weeks after icv STZ injection: hexokinase (15% 3 weeks cort.; 14% 6 weeks cort.; 12% 3 weeks hc; 28% 6 weeks hc), phosphofructokinase (15%; 15%; 24%; 15%), glyceraldehyde-3-phosphate dehydrogenase (10%; 12%; 30%; 19%), pyruvate kinase (22%; 13%; 22%; 28%), glucose-6-phosphatase (10%; 23%; 14%; 19%) and phosphorylase a (22%; 11%; 30%; 15%). The content of glycogen was significantly higher in STZ-treated rats than in control animals (7% 3 weeks and 15% 6 weeks in cortex). In contrast to the reduced enzymatic activities, we observed no changes in the concentrations of the glycolytic intermediates glucose, glucose-6-phosphate, fructose-6-phosphate, fructose-1,6-diphosphate, pyruvate, lactate and glucose-1-phosphate. These data clearly indicate reduced glycolytic enzyme activity after icv administration of STZ and suggest gluconeogenesis consequent on abnormalities in glucose breakdown. This model may thus be assumed to be a useful tool to investigate pathogenetic factors involved in sporadic dementia of Alzheimer type.
...
PMID:Action of the diabetogenic drug streptozotocin on glycolytic and glycogenolytic metabolism in adult rat brain cortex and hippocampus. 823 64

The amino acid sequence of human hexokinase II was deduced from the sequence of cDNA clones isolated from a skeletal muscle library. An open reading frame of 2751 bases encodes a protein of 917 amino acids. The deduced amino acid sequence has 94% identity with rat hexokinase II but only 72% identity with human hexokinase type I. In addition to hexokinase II clones, the human skeletal muscle cDNA library contained at least an equal number of clones of hexokinase I, the isoform reported to be typically found in kidney and brain. Genetic variation in hexokinase II could underlie insulin resistance in peripheral tissues and cause non-insulin-dependent diabetes mellitus. The availability of this sequence would facilitate investigating the role of mutations in the HKII gene in the etiology of this disease.
...
PMID:Human hexokinase II: sequence and homology to other hexokinases. 825 Sep 48

Most metabolic pathways are regulated by feedback inhibition/activation or by covalent modification of a regulatory enzyme. In erythrocytes, however, we demonstrate that glycolysis can be modulated over 30-fold by controlling the availability of glycolytic enzyme binding sites at the extreme N terminus of the anion transporter, band 3. Direct obstruction of these inhibitory sites by anti-peptide Fab's against residues 1-15 of band 3 promotes an approximately 3-fold increase in the rate of lactate production. In contrast, enrichment of the erythrocyte cytoplasm with the band 3 peptide against which the above antibodies were raised results in a more than 10-fold decrease in the rate of lactate accumulation. Control peptides and their derived antipeptide antibodies corresponding to other sequences of band 3 or glycophorin were found to have no effect on lactate production. Analysis of changes in glycolytic intermediates during Fab treatments suggests that hexokinase may be one enzyme that is modulated by association with band 3. We conclude that the extreme N terminus of band 3 can bind and inhibit glycolytic enzymes in vivo and that it probably participates in control of red cell glycolysis.
...
PMID:Regulation of glycolysis via reversible enzyme binding to the membrane protein, band 3. 832 39


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>

---